What is Cytoo?
Cytoo is a specialized biotechnology firm at the forefront of muscle pathology research. Its core offering, the MyoScreen platform, serves as a critical tool for pharmaceutical and biotechnology companies engaged in the discovery of treatments for genetic, metabolic, and neuromuscular disorders. By providing physiologically relevant cellular models through its signature CYTOOchips and CYTOOplates, the company facilitates high-precision functional potency assays and lead profiling. This unique market position allows Cytoo to bridge the gap between basic research and clinical application, effectively accelerating the timeline for therapeutic innovation and drug target validation.
How much funding has Cytoo raised?
Cytoo has raised a total of $15.9M across 3 funding rounds:
Angel/Seed
$1.2M
Series B
$4.7M
Series C
$10M
Angel/Seed (2008): $1.2M with participation from Rhône-Alpes-Creation, CEA Valorisation, and Expansinvest
Series B (2009): $4.7M led by CEA Investissement and Auriga Partners
Series C (2011): $10M supported by Auriga Partners
Key Investors in Cytoo
CEA Investissement
CEA Investissement is a venture capital firm that specializes in supporting deeptech start-ups by leveraging technologies developed within CEA laboratories, with a strong focus on life sciences and materials.
Auriga Partners
Auriga Partners is a venture capital firm that provides strategic backing to innovative companies, focusing on high-growth sectors and long-term value creation.
Expansinvest
Expansinvest is a French venture capital and private equity firm established in 1986, offering expertise in capital development, transmission, and leveraged buyouts.
What's next for Cytoo?
With the support of its recent capital injection, Cytoo is well-positioned to enhance its service offerings and deepen its integration into the global drug discovery pipeline. The company is expected to focus on scaling its MyoScreen platform to meet the increasing demand for high-fidelity disease modeling in the pharmaceutical industry. Strategic priorities likely include the expansion of its research capabilities, the pursuit of new partnerships with major biotech entities, and the continued optimization of its proprietary cellular technologies. As the firm matures, its ability to provide actionable insights into complex neuromuscular pathologies will remain a key driver of its competitive advantage and long-term commercial success.
See full Cytoo company page
